Products
Exlinkibart Biosimilar Monoclonal Antibody (4-1BB) for Research
Cat No.: GMP-Bios-INN-1197
Anti-TNFRSF9/CD137/4-1BB therapeutic antibody (Pre-made Exlinkibart biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Exlinkibart (development code LVGN-6051) is a monoclonal antibody targeting 4-1BB (TNFRSF9). It is developed by MD Anderson Cancer Center and Lyvgen Biopharma for gastric cancer, soft-tissue carcinoma, head and neck cancer among others. It is in Phase II clinical development.
Order Information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
| Catalog No. | Package | Price(In USD) |
|---|---|---|
| GMP-Bios-INN-1197-1mg | 1mg | 3090 |
| GMP-Bios-INN-1197-10mg | 10mg | |
| GMP-Bios-INN-1197-100mg | 100mg | |
| GMP-Bios-INN-1197-xmg | ≥100mg |
Product Details
| Products Name (INN Index) | Pre-Made Exlinkibart biosimilar, Whole mAb, Anti-TNFRSF9/CD137/4-1BB Antibody: Anti-TNFRSF9/CD137/Tumor necrosis factor receptor superfamily member 9/4-1BB ligand receptor therapeutic antibody |
| INN Name | Exlinkibart |
| Target | TNFRSF9/CD137/4-1BB |
| Format | Whole mAb |
| Derivation | Humanized |
| Species Reactivity | Human |
| CH1+2+3 Isotype | G1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-II |
| Est. Status | Active |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2022 |
| Year Recommended | na |
| Companies | MD Anderson Cancer Center;Lyvgen Biopharma |
| Conditions Approved | na |
| Conditions Active | Gastric cancer;Soft-tissue carcinoma;Head and neck cancer;Esophageal cancer;Hepatocellular carcinoma;Metastatic cancer |
| Conditions Discontinued | na |
| Production | na |
| Development Tech | na |
